OutSystems Announces General Availability of Mentor, a First-Of-Its-Kind Digital Worker for Application Generation and Full SDLC Automation, to Further Enhance its AI-Powered Low Code Platform
Following a successful Early Access Program, the addition of Mentor to the OutSystems platform helps enterprise development teams capitalize on the Generative Software Cycle SINGAPORE, Feb. 6, 2025 /PRNewswire/ -- OutSystems, a global leader...
YolTech Therapeutics to Initiate a Clinical Trial for YOLT-204, a First-in-Class Bone Marrow-Targeted In Vivo Gene Editing Therapy for β-Thalassemia
SHANGHAI, Jan. 21, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial for YOLT-204, an investigational therapy for the treatment of...
Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy
ACE2016 Is an Allogeneic Gamma Delta 2 (γδ2) T Cell Therapy Targeting the Epidermal Growth Factor Receptor (EGFR) in Patients With Solid Tumors. Phase 1 Clinical Study Expected to Begin in H2 2024. ALAMEDA, Calif. and TAIPEI, Feb. 5, 2024...
